Aclaris Therapeutics, Inc.
ACRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001557746
No open-market purchases or sales by Aclaris Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $630.0M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Aclaris Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 115 | 1 | 127 | +13 |
| Shares | 63.3M | 36.7K | 63.6M | +335.8K (+0.5%) |
| Value | $883.3M | $587.0K | $1.00B | +$117.8M (+13.3%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held Aclaris Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Walleye Capital LLC | 269,948 | $4.25M | 0.10% |
| Balyasny Asset Management LLC | 106,147 | $1.67M | 0.01% |
| Allspring Global Investments Holdings, LLC | 66,136 | $1.04M | 0.00% |
| Candriam Luxembourg S.C.A. | 56,279 | $886.0K | 0.01% |
| Teachers Retirement System of the State of Kentucky | 54,011 | $850.0K | 0.01% |
| Dimensional Fund Advisors LP | 48,017 | $756.0K | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 26,854 | $423.0K | 0.00% |
| Susquehanna International Group, LLP | 22,536 | $355.0K | 0.00% |
| Walleye Trading LLC | 21,026 | $331.0K | 0.01% |
| AXA S.A. | 18,200 | $286.5K | 0.00% |
| Alberta Investment Management Corp | 15,756 | $248.0K | 0.00% |
| Fox Run Management, L.L.C. | 14,928 | $235.0K | 0.09% |
| SG Americas Securities, LLC | 13,598 | $214.0K | 0.00% |
| Amundi | 3,975 | $63.0K | 0.00% |
| Simplex Trading, LLC | 972 | $15.0K | 0.00% |
| China Universal Asset Management Co., Ltd. | 624 | $10.0K | 0.00% |
| Signaturefd, LLC | 101 | $2.00K | 0.00% |
| US Bancorp | 67 | $1.00K | 0.00% |
| Wipfli Financial Advisors LLC, | 68 | $1.00K | 0.00% |
Sold out (6)
Institutions that held Aclaris Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Weiss Multi-Strategy Advisers LLC | 15,000 | $209.0K |
| Tudor Investment Corp Et Al | 12,090 | $169.0K |
| Occudo Quantitative Strategies LP | 11,799 | $165.0K |
| Telemetry Investments, L.L.C. | 11,043 | $154.0K |
| Captrust Financial Advisors | 61 | $1.00K |
| Quadrant Capital Group LLC | 84 | $1.00K |
Not filed for Q3 2022 yet (1)
Institutions that held Aclaris Therapeutics, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| HighPoint Advisor Group LLC | 36,739 | $587.0K |